Skip to main content
OPKO Health Inc. logo

OPKO Health Inc. — Investor Relations & Filings

Ticker · OPK ISIN · US68375N1037 LEI · 529900A4S2D4OGOJLL02 TA Human health and social work activities
Open in API
Filings indexed 3,780 across all filing types
Latest filing 2024-09-16 Delisting Announcement
Country US United States of America
Listing TA OPK

About OPKO Health Inc.

https://www.opko.com

OPKO Health, Inc. is a fully-integrated healthcare company operating in both pharmaceuticals and diagnostics. Its pharmaceutical division develops and commercializes novel therapies for serious diseases. Key marketed products include NGENLA™, a long-acting treatment for pediatric growth hormone deficiency partnered with Pfizer, and RAYALDEE®. The company's research focuses on advancing multispecific therapies for cancers and infectious diseases. Through its subsidiary, BioReference Laboratories, OPKO operates one of the largest full-service clinical reference laboratories in the U.S., providing comprehensive diagnostic testing services to millions of patients annually.

Recent filings

Filing Released Lang Actions
Form 8-K-Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Delisting Announcement Classification · 99% confidence The document explicitly states it is a "FORM 8-K CURRENT REPORT" filed with the SEC on September 16, 2024. Form 8-K is used to announce major events that shareholders should know about. The content details the completion of an asset disposition (Item 2.01) and the termination of a credit agreement (Item 1.02), along with the filing of pro forma financial information (Item 9.01). While the document includes a press release (Item 7.01, Exhibit 99.1) announcing the completion of the acquisition, the primary filing structure is the Form 8-K itself, which reports material events. Reviewing the provided filing codes, there is no specific code for Form 8-K. Form 8-K reports material, unscheduled events. The closest categories are: - ER (Earnings Release): Incorrect, this is an M&A/financing event. - CAP (Capital/Financing Update): Partially relevant due to debt termination, but the main event is asset disposition. - TAR (M&A Activity): Relevant due to the asset sale. - RNS (Regulatory Filings): This is the general fallback for SEC filings that don't fit specific categories like 10-K, IR, or DEF 14A. Since Form 8-K is a mandatory, general-purpose regulatory filing for material events not covered by other periodic reports, and given the lack of a specific 8-K code, the most appropriate classification is the general regulatory fallback category, RNS (Regulatory Filings). The document length (43,950 chars) is substantial, confirming it is the filing itself, not just a brief announcement (ruling out RPA/RNS based on the 'Menu vs Meal' rule if it were just an announcement, but here the 8-K structure dominates). Therefore, classifying it as RNS (Regulatory Filings) as the catch-all for non-periodic SEC reports.
2024-09-16 English
Form 8-K-Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Regulatory Filings Classification · 95% confidence The document explicitly mentions 'Form 8-K' and describes the consummation of an Asset Purchase Agreement between BioReference and LabCorp on September 16, 2024. It is an immediate report filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE), referencing a US filing (Form 8-K). A Form 8-K is used to announce major events that shareholders should know about. Since this document is short (2125 chars) and primarily serves to announce the filing of the actual Form 8-K (referenced as '20240916_Form_8-K_isa.pdf'), it fits the definition of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given the specific nature of announcing the publication of a material report (Form 8-K), RPA is more precise than the general RNS fallback, although RNS is also plausible if RPA is reserved strictly for company-issued reports. However, since it is an official regulatory filing announcing a material event and attaching/referencing the primary document, and it doesn't fit the comprehensive report categories (10-K, IR, ER), it falls best under the general regulatory announcement category, RNS, as it is a notification of a material event filing.
2024-09-16 English
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
M&A Activity Classification · 95% confidence The document is formatted as a press release, indicated by the "FOR IMMEDIATE RELEASE" header and contact information for investors and media. The content announces the completion of a major corporate transaction: Labcorp's acquisition of select assets from OPKO Health's BioReference Health business. This type of announcement, detailing a significant corporate event (M&A activity) via a press release, is typically classified as a general Regulatory Filing (RNS) if a more specific category like TAR (M&A Activity) is not strictly required for the *announcement* itself, or if it doesn't fit the strict definitions of the other codes. Since the document explicitly details a merger/acquisition event, the most appropriate specific category is 'M&A Activity' (TAR). However, looking at the definitions, TAR is for 'merger proposals or takeover bids.' This is the *completion* of an acquisition. Since it is a formal announcement of a significant corporate action, and it is not a financial report (10-K, IR, ER), nor a management/board change (MANG), nor a financing event (CAP), it falls best under the general regulatory announcement category, RNS, or potentially TAR if we interpret 'M&A Activity' broadly to include closing announcements. Given the nature of the content (a definitive announcement of a completed acquisition), TAR is the most precise fit for the subject matter, even if it's the closing rather than the proposal. If TAR is strictly for proposals/bids, RNS is the fallback. Since the document is a formal announcement of a major transaction, I will classify it as M&A Activity (TAR) as it is the most descriptive category for the event being reported.
2024-09-16 English
Labcorp Completes Acquisition of Select Assets of BioReference Health's Diagnostics Business from OPKO Health
Report Publication Announcement Classification · 98% confidence The document is very short (1799 characters) and explicitly states, "Attached hereto is a report on*������ ����� ��� ������� ���������.* *20240916_PR_LH_BioReference_isa.pdf*". This structure indicates that the current filing is an announcement about the publication of another document, rather than the full report itself. It is filed with the Israel Securities Authority (ISA) and the Tel Aviv Stock Exchange (TASE) as an 'Immediate Report' under Regulation 4 for a foreign private issuer. Since it is an announcement of a report's release and does not fit the specific definitions for 10-K, IR, ER, or other specific report types, it best matches the 'Report Publication Announcement' (RPA) category, which covers announcements regarding the release of company reports.
2024-09-16 English
Schedule 14A, Amendment No.1 - amendment to the proxy statement of OPKO filed on February 29, 2024
Proxy Solicitation & Information Statement Classification · 100% confidence The document explicitly states it is a "SCHEDULE 14A (Amendment No. 1)" and a "Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934." It also mentions "Definitive Additional Materials" and contains detailed tables regarding "Pay Versus Performance" compensation disclosures, which are mandated for proxy statements under Regulation S-K Item 402(v). This content directly relates to soliciting shareholder votes and providing required executive compensation disclosure ahead of a shareholder meeting, fitting the definition of a Proxy Statement/Solicitation Material. The closest matching category is PSI (Proxy Solicitation & Information Statement), although DEF 14A (Remuneration Information) is also highly relevant due to the focus on compensation, PSI is broader and covers the entire proxy document structure (Schedule 14A). Given the explicit Schedule 14A filing, PSI is the most accurate classification.
2024-08-31 English
Schedule 14A, Amendment No.1 - amendment to the proxy statement of OPKO filed on February 29, 2024
Proxy Solicitation & Information Statement Classification · 98% confidence The document explicitly mentions 'Schedule 14A, Amendment No.1 - amendment to the proxy statement of OPKO Health, Inc. filed on February 29, 2024.' A Schedule 14A is the SEC form for a Proxy Statement, which solicits shareholder votes for the Annual Meeting. The definition for Proxy Solicitation & Information Statement is 'PSI'. However, the definition for 'DEF 14A' is 'Remuneration Information' and the definition for 'PSI' is 'Proxy Solicitation & Information Statement'. Since Schedule 14A is the core document for proxy solicitation, PSI is the most appropriate fit among the provided codes, even though the document is an amendment to a proxy statement. Furthermore, the document is a regulatory filing announcement (mentioning ISA and TASE) that references the proxy material, but given the specific nature of Schedule 14A, PSI is preferred over the general RPA or RNS.
2024-08-31 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.